Most importantly, by inhibiting RORγ transcriptional activity and thereby reducing Th17 generation and IL-17A/F production, RORγ inverse agonists may provide a novel strategy in the treatment of various pathologies in which RORγ is implicated, including inflammatory, metabolic, endocrine, and autoimmune diseases [1, 2, 13, 25, 257, 258]. The gene discussed is IL17A; the disease is autoimmune disease.